Educate Why Aduhelm Isn’t a Miracle for Alzheimer’s
You’ll hear controversy about Aduhelm (aducanumab), the first new med for Alzheimer’s disease in almost 20 years.
It’s a monoclonal antibody given as an IV infusion every 4 weeks.
Patients with Alzheimer’s and their families are often looking for a glimmer of hope.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote